November is Lung Cancer Awareness Month, and Main Line Health reminds all members of the community to be proactive in improving their lung health. Patients who have been diagnosed with lung cancer may want to discuss with their health care providers if participation in a clinical research study is an available option for them.
“In 2018, about 234,000 Americans received a diagnosis of lung cancer, according to the American Lung Association. Research is essential for advancing health care and can lead to medical breakthroughs that improve and save lives,” said Paul Gilman, MD, director of the Clinical Research Center at the Lankenau Institute for Medical Research, which is part of Main Line Health. “By participating in clinical trials, participants may have access to potential new health care choices and the opportunity to help advance medical knowledge.”
Several clinical studies currently available at Main Line Health are testing new potential treatment options, including new medications and radiotherapy protocols for various stages of lung cancer. Researchers also seek to screen for and identify certain genetic mutations in lung cancer patients to help guide physicians to the most appropriate treatment options.
Other research studies that are exploring new therapies and ways to help manage side effects and lifestyle changes that may accompany lung cancer are also recruiting patients. The cancer team at the Clinical Research Center can help guide patients and their physicians through the opportunities available.
For more on the lung cancer clinical trials available at Main Line Health, visit mainlinehealth.org/lungclinicaltrials.
Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.
At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
The Main Line Health system also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award, and recognition as among the nation’s best employers by Forbes magazine. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.